Combined-modality radioimmunotherapy: synergistic effect of paclitaxel and additive effect of bevacizumab
about
Combination Radioimmunotherapy Approaches and Quantification of Immuno-PETPaclitaxel improved anti-L1CAM lutetium-177 radioimmunotherapy in an ovarian cancer xenograft model.Triple stimulus-responsive polypeptide nanoparticles that enhance intratumoral spatial distribution.Radioimmunoconjugates for treating cancer: recent advances and current opportunities.Relevance of radiobiological concepts in radionuclide therapy of cancer.
P2860
Combined-modality radioimmunotherapy: synergistic effect of paclitaxel and additive effect of bevacizumab
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Combined-modality radioimmunot ...... additive effect of bevacizumab
@ast
Combined-modality radioimmunot ...... additive effect of bevacizumab
@en
type
label
Combined-modality radioimmunot ...... additive effect of bevacizumab
@ast
Combined-modality radioimmunot ...... additive effect of bevacizumab
@en
prefLabel
Combined-modality radioimmunot ...... additive effect of bevacizumab
@ast
Combined-modality radioimmunot ...... additive effect of bevacizumab
@en
P2093
P2860
P1476
Combined-modality radioimmunot ...... additive effect of bevacizumab
@en
P2093
Beom-Su Jang
Chang H Paik
Faezeh Razjouyan
Hyung Sub Kim
In Soo Shin
Ira Pastan
Matthew R Dreher
Sang-Myung Lee
Shutao Wang
Zhengsheng Yao
P2860
P304
P356
10.1016/J.NUCMEDBIO.2011.10.020
P577
2011-12-14T00:00:00Z